Best Practice Guide: Continuous subcutaneous insulin infusion (CSII) A clinical guide for adult diabetes services

This document aims to provide healthcare professionals with UK expert consensus on the best practice for managing and optimising CSII.

PDF File Download

Best Practice Guide: Continuous subcutaneous insulin infusion (CSII) A clinical guide for adult diabetes services

Discipline:

Diabetes

Clinical taxonomy:

Pumps and pump technology

Treatments for diabetes

Resource taxonomy:

Diabetes Technology Network (DTN-UK)

Address for correspondence: ABCD (Diabetes Care) Ltd, Miria House, 1683b High Street, Knowle, Solihull, West Midlands, B93 0LL

Telephone: 01675 477602 Facsimile: 01361 331 811 Email: info@abcd.care

ABCD (Diabetes Care) is a company limited by shares in England and Wales under company number 7270377, whose registered address is Sterling House, 1 Sheepscar Court, Meanwood Road, Leeds LS7 2BB. Diabetes Care Trust (ABCD) is a registered charity number 1139057, a company limited by guarantee in England and Wales under company number 74248361,whose registered address is Sterling House, 1 Sheepscar Court, Meanwood Road, Leeds LS7 2BB. ABCD (Diabetes Care) Ltd is a wholly owned subsidiary of the Diabetes Care Trust (ABCD) Ltd

ABCD Corporate Pharma Sponsors; Gold: AstraZeneca, Lilly, Novo Nordisk Ltd, Sanofi Diabetes; Bronze: Napp Pharmaceuticals Limited

ABCD Corporate Pump & Device Supporters, Gold: Abbott Diabetes Care, Roche Diabetes Care, Ypsomed Ltd; Silver: Advanced Therapeutics (UK) Ltd, Dexcom, Medtronic Ltd; Bronze: Insulet International Ltd

Read the ABCD statement on pharmaceutical industry funding

Best Practice Guide: Continuous subcutaneous insulin infusion (CSII) A clinical guide for adult diabetes services

Information for HCPs

ABCD Webinar Series

Search form

You are here

Best Practice Guide: Continuous subcutaneous insulin infusion (CSII) A clinical guide for adult diabetes services

Information for HCPs

ABCD Webinar Series